

MASTER CTA LABEL



Protocol/ Study title: Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses

Sponsor code: PRINCIPLE

EudraCT no: 2020-001209-22

IPS code: PPRI03001

Version: 01

CTA Label

Dose instructions:

Day 1: Five tablets (2000mg)

Favipiravir to be taken in the morning, and Four tablets (1600mg) taken in the evening.

Day 2 - 5: Take two tablets (800mg) twice daily for four days.

Special Instructions: Those taking this medication must avoid excessive exposure to sunlight or artificial ultraviolet light. Do not take more than 6 Paracetamol in 24 hours.

IPS lot No:

Batch no:

Expiry:

25 Favipiravir

400 milligram (mg)
tablets

For Oral Use Only

Store at room temperature
(1°C-30°C) and
shield from direct light

Participant ID:

Pack ID:

For Clinical Trial Use Only

**Keep out of the reach
and sight of children**

Chief Investigator:

Prof. Chris Butler

University of Oxford

Joint Research Office

1st floor,

Boundary Brook House,

Churchill Drive, Headington,

Oxford, OX3 7GB


Tel: +44 (0)1865 572 224

Fax: +44 (0)1865 572 228

Sponsor: University of Oxford

Trial Ref. Code: PRINCIPLE

Period of use: 5 days

	Name	Title	Signature and Date
Created by	Sanjay Patel	Head of Technical	 01 APR 2022
Approved By	Jared Robinson	Trial Manager	 01 Apr 2022

Author	Bibiana George	Reviewer	Ashok Patel	Approver	Amanda Peter
Initial/Date	185 23 Feb 2021	Initial/Date	ELM 23 Feb 2021	Initial/Date	P.P. 16 23 FEB 2021
Issue Date	23 FEB 2021	Effective Date	24 FEB 2021	Review Date	23 FEB 2024
PQS Ref: CCF 21-022	Associated SOP: 069	Appendix: 06	Revision No. 01	Page 1 of 1	